Status
Conditions
Treatments
About
Evaluating the nutrition status of patients with advanced HCC who received sorafenib.
Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
Full description
This a cross sectional study will be conducted on 100 HCC treated with sorafenib Data were gathered from medical records, including
age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC
Barcelona Clinic Liver Cancer Stage (BCLC) of all patients
The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count.
The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count.
Weight loss difference after treatment Portal hypertension was defined as presence of either collaterals on radiological examination, esophageal varices by upper gastrointestinal endoscopy and/or thrombocytopenia.
Quality of life assessment. QoL was assessed using FACT Hepatobiliary Symptom Index (FHSI-8) Questionnaire. QoL was assessed at base line and 3-6 months after start of treatment.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
80 participants in 1 patient group
Loading...
Central trial contact
Mona Abdelrahmam, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal